Efforts to control sexually transmitted infections as a means to limit HIV transmission: What is the evidence?

Current Infectious Disease Reports

Volumn 7, Issue 1, 2005, Pages 79-84

  Dallabetta, Gina ^a   Neilsen, Graham ^b  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHLAMYDIASIS; COMMUNITY CARE; CONDOM; DISEASE COURSE; GONORRHEA; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH SERVICE; HETEROSEXUALITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RISK; INFECTION SENSITIVITY; KENYA; MALAWI; MASS SCREENING; PATIENT COUNSELING; PREVALENCE; PROSTITUTION; RISK FACTOR; SAFE SEX; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TANZANIA; TRICHOMONAS VAGINALIS; UGANDA; VAGINITIS; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 13544265646     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-005-0027-8     Document Type: Article

References (51)

1. UNAIDS report: most deaths and new infections ever; some good news. AIDS Treat News 2003, (396)3.
2. Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000, 342:921-929.
3. Baeten JM, Mostad SB, Hughes MP, et al.: Selenium deficiency is associated with shedding of HIV-1 infected cells in the female genital tract. J Acquir Immune Defic Syn 2001, 26: 60-364.
4. Mostad SB, Overbaugh J, De Vange DM, et al.: Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infection cells from the cervix and vagina. Lancet 1997, 350:922-927.
5. Koopman JS, Jacquez JA, Welch GW, et al.: The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syn 1997, 14:56-62.
6. Gray RH, Wawer MJ, Serwadda D, et al.: Determinants of HIV-1 viral load in subjects with early and later HIV infection, in a general-population cohort of Rakai, Uganda. J Infect Dis 2004, 189:1209-1215.
7. Lehner T: The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol 2002, 23:347-351.
8. Siegfried N, Muller M, Volmink J, et al.: Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev 2003, (3):CD003362.
9. Sangani P, Rutherford G, Wilkinson D: Population-based interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Database Syst Rev 2004, (2 ):CD001220.
10. Galvin SR, Cohen MS: The role of sexually transmitted disease in HIV transmission. Nat Rev Microbiol 2004, 2: 3-42.
11. Rottingen JA, Cameron DW, Garnett GP: A systematic review of the epidemiologic interactions between classic sexually transmitted disease and HIV: How much really is known? Sex Transm Dis 2001, 28:579-597.
12. UNAIDS/WHO: Consultation on STD Interventions for Preventing HIV: What is the evidence? UNAIDS, Geneva, Switzerland, May 2000.
13. Fleming DT, Wasserheit JN: From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999, 75:3-17.
14. Hobbs M, Kazemba P, Reed A, et al.: Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis 1999, 26:381-387.
15. Price MA, Zimba D, Hoffman IF, et al.: Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex Transm Dis 2003, 30: 16-522.
16. Mbopi-Keou FX, Gresenguet G, Mayaud P, et al.: Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for interventions. J Infect Dis 2000, 182:1090-1096.
17. McClelland RS, Wang CC, Overbaugh J, et al.: Association between cervical shedding of herpes simplex virus and HIV1. AIDS 2002, 16:2425-2437.
18. Pilcher CD, Price MA, Hoffman IF, et al.: Frequent detection of acute primary HIV infection in men in Malawi. AIDS 2004, 18:517-524.
19. Rotchford K, Sturm AW, Wilkinson D: Effect of coinfection with STDs and of STD treatment on HIV shedding in genital-tract secretions: systematic review and data synthesis. Sex Transm Dis 2000, 27:243-248.
20. McClelland RS, Wang CC, Mandaliya K, et al.: Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001, 15:105-110.
21. Anzala AO, Simonsen JN, Kimani J, et al.: Acute sexually transmitted infection increase human immunodeficiency virus type 1 plasma viremia, increase plasma type 2 cytokines and decrease CD4 cell counts. J Infect Dis 2000, 182:459-466.
22. Nkengasong JN, Kestens L, Ghys PD, et al.: Human immunodeficiency virus type-1 (HIV1) plasma virus load and markers of immune activation among HIV-infected female sex workers with sexually transmitted diseases in Abidjan, Cote d'Ivoire. J Infect Dis 2001, 183:1405-1408.
23. Cohen MS, Hoffman IF, Royce RA, et al.: Reduction of concentration of HIV1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV1. Lancet 1997, 349:1868-1873.
24. Schacker T, Zeh J, Huilin H, et al.: Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002, 186:1718-1725.
25. Buchacz K, Patel P, Taylor M, et al.: Syphilis infection increases HIV viral load in HIV-infected men. Paper presented at the National HIV Prevention Conference. Atlanta, Georgia, July 27-30, 2003.
26. Miller CJ, Shattock RJ: Target cells in vaginal HIV transmission. Microbes Infect 2003, 5:59-67.
27. Levine WC, Pope V, Bhoomkar A, et al.: Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis 1998, 177:167-174.
28. Coombs RW, Reichelderfer PS, Landay AL: Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003, 17:455-480.
29. Wald A, Link K: Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002, 185:45-52.
30. Del Mar Pujades Rodríguez M, Obasi A, Mosha F, et al. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS 2002, 16: 51-462.
31. Reynolds SJ, Risbud AR, Shepherd ME, et al.: Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003, 187:1513-1521.
32. Renzi C, Douglas JM, Foster M, et al.: Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men. J Infect Dis 2003, 187:19-25.
33. The HIV Trials Prevention Network: HPTN 039 A Phase III, randomized, double-blind, placebo-controlled trial of acyclovir for the reduction of HIV acquisition among high risk HSV-2 seropositive, HIV-seronegative individuals. http://www.hptn.org/research_studies/hptn039.asp.Accessed January 8,2004.
34. The Bill & Melinda Gates Foundation: Gates Foundation provides $30 million grant for first-ever study of Herpes treatment to reduce HIV transmission. http://www.gatesfoundation.org/GlobalHealth/HIVAIDSTB/HIVAIDS/ Announcements/Announce-030724.htm.Accessed April 18, 2004.
35. Grosskurth H, Mosha F, Todd J, et al.: Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomized controlled trial. Lancet 1995, 346:530-536.
36. Mayaud P, Mosha F, Todd J, et al.: Improved treatment services significantly reduce the prevalence of sexually transmitted diseases in rural Tanzania: results of a randomized controlled trial. AIDS 1997, 11:1873-1880.
37. Orroth KK, Gavyole A, Todd J et al.: Syndromic treatment of sexually transmitted disease reduces the proportion of incident HIV infections attributable to these diseases in rural Tanzania. AIDS 2000, 14:1429-1437.
38. Wawer MJ, Sewankambo NK, Serwadda D, et al.: Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomized community trial. Lancet 1999, 353:525-535.
39. Gray RH, Wawer MJ, Sewankambo NK, et al.: Relative risks and population attributable fraction of incident HIV associated with symptoms of sexually transmitted diseases and treatable symptomatic sexually transmitted diseases in Rakai District, Uganda. AIDS 1999, 13:2113-2123.
40. Kamali A, Quigley M, Nakiyingi J, et al.: Syndromic management of sexually-transmitted infections and behavior change interventions on transmission of HIV-1 in rural Uganda: a community randomized trial. Lancet 2003, 361:645-652.
41. Grosskurth H, Gray R, Hayes R, et al.: Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet 2000, 355:WA8-WA14.
42. Boily MC, Lowndes CM, Alary M: Complementary hypothesis concerning the community sexually transmitted disease mass treatment puzzle in Rakai, Uganda. AIDS 2000, 14:2583-2592.
43. Orroth KK, Korenromp EL, White RG, et al.: Comparison of STD prevalences in the Mwanza, Rakai, and Masaka trial populations: the role of selection bias and diagnostic errors. Sex Transm Infect 2003, 79:98-105.
44. Orroth KK, Korenromp EL, White RG, et al.: Higher risk behaviour and rates of sexually transmitted diseases in Mwanza compared to Uganda may help explain HIV prevention trial outcomes. AIDS 2003, 17:2653-2660.
45. Orroth K, White RG, Bakker R, et al.: Proportion of HIV infection attributable to sexually transmitted disease in Mwanza and Rakai - results of a simulation model. Paper presented at the 2003 International Society for Sexually Transmitted Disease Research Congress Ottawa, Canada, July 27-30, 2003.
46. Korenromp EL, Bakker R, deVlas SJ et al.: HIV dynamics and behavior change as determinants of the impact of sexually transmitted disease treatment on HIV transmission in the context of the Rakai trial. AIDS 2002, 16:2209-2218.
47. Kaul R, Kimani J, Nagelkerke NJ, et al.: Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infection and HIV1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004, 291:2555-2562.
48. Kaul R, Kimani J, Nagelkerke MJ, et al.: Reduced HIV risk-taking and low HIV incidence after enrollment and risk-reduction counseling in a sexually transmitted disease prevention trial in Nairobi, Kenya. J Acquir Immune Defic Syndr 2002, 30:69-72.
49. Steen R, Dallabetta G: Sexually transmitted infection control in sex workers: regular screening and presumptive treatment augment efforts to reduce risk and vulnerability. Reprod Health Matters 2003, 11:74-90.
50. Monitoring the AIDS Pandemic report AIDS in Asia: face the facts - a comprehensive analysis of the AIDS epidemics in Asia. Monitoring the AIDS Pandemic report. 2004. http://www.mapnetwork.org/reports/aids_in_asia.html). Accessed April 18, 2004.
51. Moses S, Ngugi EN, Costigan A, et al.: Response of a sexually transmitted infection epidemic to a treatment and prevention programmed in Nairobi. Sex Transm Infect 2002, 78(Suppl-1): 114-i120.